William Ashton is Director at Sucampo Pharmaceuticals, Inc. (SCMP). They have made 2 open-market trades across 2 companies since 2015, most recently 2024-04-08.
CIK 0001474553
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2023, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SCTL | BUY | 2023-08-28 | 2023-08-28 | $0.46 | $10K | +28.5% | -2.1% | -18.3% |
| SPPI | SELL · 10b5-1 | 2022-06-21 | 2022-06-22 | $0.79 | $3K | -4.8% | +0.2% | -20.9% |
| SPPI | SELL · 10b5-1 | 2021-06-18 | 2021-06-22 | $4.24 | $38K | -9.0% | -16.8% | -42.0% |
| SPPI | SELL · 10b5-1 | 2020-06-22 | 2020-06-23 | $3.25 | $16K | +10.0% | +1.9% | +48.3% |
| SPPI | SELL · 10b5-1 | 2019-06-19 | 2019-06-21 | $8.57 | $57K | +7.4% | -6.7% | +15.2% |
| SCMP | SELL | 2015-03-11 | 2015-03-18 | $17.42 | $2.3M | -21.8% | -3.5% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.